Still-in-stealth biotech partners with Sloan Kettering scientists to make personalized cancer therapy more ‘public’
One of the obstacles of personalized medicine is that it is, well, personalized. With cancer therapies especially, personalized treatments take money, time, resources and access — all of which are finite.
But some scientists instead want to take a more “public” approach to what has traditionally been a therapy tailored to individual tumors. The vast majority of neoantigens — mutated protein bits exclusively made by cancers — are “private,” meaning that they are unique to a single tumor and person. So while their specificity makes them a good target, private neoantigens may be too specific.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.